Oral Glucose Tolerance Test Clinical Trial
Official title:
Non-Invasive Glucose Measurement Using Raman Spectroscopy During Oral Glucose Tolerance Test
This study is to evaluate the capability of Raman spectroscopy as a non-invasive method for monitoring concentrations of glucose by illuminating a small spot on the skin, collecting and analyzing the return light. The glucose measurements obtained by Raman Spectroscopy are correlated with those obtained using YSI glucose analyzer and ACCUCHECK instruments.
Diabetes mellitus (DM), caused by impairment in the glucose metabolism is a worldwide
epidemic. It is projected that by the year 2035 there will be approximately 592 million
diabetic patients. Blood glucose (BG) levels are finely regulated by insulin secretion and
any defects in the secretion or function can lead to DM. As no well-established medical
intervention for DM has been known till date, continuous monitoring of BG is the only way to
avoid secondary metabolic complications such as strokes, heart attacks, high blood pressure,
blindness and coma. Diagnosis and therapeutic monitoring of diabetes requires direct
measurement of plasma (or blood) glucose. Measurement of the fasting glucose level is the
preferred test for diagnosis of diabetes in children and non-pregnant adults, while the oral
glucose tolerance test (OGTT) is the preferred method of diagnosis for gestational diabetes.
In addition, patients with an established diagnosis of insulin-dependent diabetes (all type-I
and many type-II) require frequent glucose measurements for therapeutic monitoring. Emergence
of hand-held glucose sensors have enabled patients with the ability to self-monitor the BG
level. The frequent monitoring requires small blood sample (<1 µL) obtained by a
"finger-pricking" and electrochemical sensing using a portable 'glucometer'. However the
procedure is inconvenient, results in poor patient compliance and lacks in providing real
time information about concentration changes. Regardless of the clinical test performed,
withdrawal of blood or interstitial fluid is currently required for measurement of BG levels.
The proposed study is based on preliminary research supported by the MIT Laser Biomedical
Research Center (LBRC), and promising results obtained with spectroscopic measurement of
blood glucose in the laboratory, in an experimental animal model, and in a small cohort of
human subject volunteers. In order to make non-invasive glucose measurement a viable clinical
technology, however, a methodological implementation and validation from bench to bedside is
required. In the application, we propose to accomplish this goal by means of a
carefully-designed translational research study employing specifically-designed
instrumentation and methods for pre-clinical validation and early clinical studies in human
subjects. These studies will incrementally increase in data complexity, culminating in a
clinical study in human subjects, as well as a non-invasive, spectroscopic glucose tolerance
test as an alternative to OGTT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05989867 -
Evaluation of OGTT in Patients With Post-pancreatitis Diabetes Mellitus for Diagnosis and Characterization
|
||
Completed |
NCT03506581 -
Dysfunctional Adiposity and Glucose Impairment
|
||
Completed |
NCT06400836 -
Nutrient Timing in Connection to Evening Exercise
|
N/A | |
Completed |
NCT04144595 -
Association Between Low Plasma Glucose After Oral Glucose Tolerance Test in Pregnancy With Impaired Fetal Growth
|
||
Completed |
NCT02894112 -
Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal
|
N/A |